FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to an isolated antigen-binding polypeptide which binds to CD47, and an antigen-binding portion thereof, as well as to an immunoconjugate and a composition containing them.
EFFECT: invention is effective for reducing a tumour in a subject in need thereof, as well as for treating an oncological disease in a subject in need thereof.
22 cl, 11 dwg, 21 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CD47-ANTIGEN-BINDING UNIT AND ITS USE | 2018 |
|
RU2780859C2 |
| Therapeutic antibodies to CD47 | 2016 |
|
RU2748401C2 |
| FUNCTION PROTEIN AND ITS USE | 2019 |
|
RU2800923C2 |
| ANTIBODIES AGAINST SIGNAL-REGULATORY ALPHA PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2771964C2 |
| PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF THEIR USE | 2019 |
|
RU2800779C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| FUSION PROTEIN AND ITS USE | 2020 |
|
RU2811120C2 |
| ANTIBODY AGAINST SIRPα | 2019 |
|
RU2791002C2 |
| BINDING OF FUSED PROTEIN TO CD47 PROTEIN AND ITS USE | 2019 |
|
RU2787521C2 |
